<DOC>
	<DOCNO>NCT00450333</DOCNO>
	<brief_summary>The purpose study demonstrate non-inferiority efficacy twice weekly weekly dose schedule Dynepo previously erythropoietin ( EPO ) -naive patient , measure haemoglobin week 24 secondly demonstrate non-inferiority efficacy weekly every two week dose schedule Dynepo patient previously stable EPO , measure Hb Weeks 16 24 .</brief_summary>
	<brief_title>Dynepo Infrequent Dosing Study</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Aged least 18 year chronic kidney disease ( Kidney Disease Outcomes Quality Initiative [ KDOQI ] stage IIIV ) . Stable take dos &lt; = 10,000 IU/week subcutaneous ( sc ) EPO require initiation EPO . Transferrin saturation &gt; = 20 % ferritin &gt; = 100 ng/mL . Uncontrolled hypertension . Requiring dos EPO &gt; 10,000 IU/week . Two dos prescribe EPO treatment miss ot withheld physician order 14 day immediately prior tp randomisation study . Active bleed disorder ( diathesis ) ( example , Gastrointestinal Genitourinary tract bleed ) . Treatment immunosuppressive drug ( corticosteroid chronic condition ) 30 day immediately prior randomisation study . Androgen therapy 30 day immediately prior randomisation study . Known Human Immunodeficiency Virus ( HIV ) infection . History hypersensitivity EPO therapy excipients Dynepo .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Chronic</keyword>
</DOC>